TYTenghua Yu

Tenghua Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tenghua Yu has a total of 84 co-authors. Here are the top co-authors by number of shared publications:

  • Jiawei Xu

    Jiangxi medical college Nanchang University Nanchang China

    6 shared publications
  • Xiaoqiang Zeng

    Department of Breast Surgery, Jiangxi Cancer Hospital & Institute, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Key Laboratory of Oncology (2024SSY06041), Jiangxi Clinical Research Center for Cancer, JXHC Key Laboratory of Tumor Microenvironment and Immunoregulation, Jiangxi Key Laboratory of Tumor Metastasis of Jiangxi Health Commission, Nanchang, Jiangxi 330029, China

    6 shared publications
  • Yanxiao Huang

    Department of Breast Surgery, Jiangxi Cancer Hospital & Institute, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Key Laboratory of Oncology (2024SSY06041), Jiangxi Clinical Research Center for Cancer, JXHC Key Laboratory of Tumor Microenvironment and Immunoregulation, Jiangxi Key Laboratory of Tumor Metastasis of Jiangxi Health Commission, Nanchang, Jiangxi 330029, China

    6 shared publications
  • Zhengkui Sun

    Jiangxi Medical College, Nanchang University, Nanchang, China

    4 shared publications
  • Chengdong Yu

    Jiangxi Medical College, Nanchang University, Nanchang, China

    3 shared publications
  • Chongwu He

    Department of Breast Surgery, Jiangxi Cancer Hospital & Institute, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Key Laboratory of Oncology (2024SSY06041), Jiangxi Clinical Research Center for Cancer, JXHC Key Laboratory of Tumor Microenvironment and Immunoregulation, Jiangxi Key Laboratory of Tumor Metastasis of Jiangxi Health Commission, Nanchang, China

    3 shared publications

Latest Publications

  • Open Access

    Knowledge and attitudes among high school students toward medical misinformation and their willingness to pursue medical-related majors

    by Yingge Mou, Zhiliang Wang, Guoyuan Li, Xiaosong Li, Tenghua Yu, Ben Wang, Yuanzhi Wu, Bing Yang, Hong Zhao

    With the rise of the Internet and social media, misinformation has become more prevalent and easier to access. This study aimed to assess the knowledge and attitudes among high school students toward medical misinformation and their willingness to pursue medical-related majors. This cross-sectional study enrolled high school students in China between December 2022 and January 2023. A total of 2002 valid questionnaires were collected. The knowledge, attitude, and willingness scores were 7.81 ± 3.02 (possible range: 0–12), 34.73 ± 4.56 (possible range: 9–45), and 30.98 ± 7.50 (possible range: 9–45), respectively. The multivariable analysis showed that attitude score (β = 0.803, 95% CI: 0.730–0.875, P < .001), age beyond 19 (β = 2.558, 95% CI: 0.596–4.520, P = .011), nontechnical high school (β = −1.549–3.358, all types P < .01), Grade III (β = 1.598, 95% CI: 0.752–2.444, P < .001), and having immediate family member engaged in medicine (β = 1.814, 95% CI: 0.736–2.892, P = .001) were associated with a higher willingness score. Additionally, structural equation modeling indicated that knowledge was associated with attitude (β = 0.727, P < .001), and attitude was associated with willingness (β = 0.806, P < .001). High school students demonstrated limited knowledge and low confidence in dealing with medical misinformation, along with only moderate willingness to pursue medical-related majors, despite generally recognizing the importance of combating misinformation. This study underscores the need to enhance high school students’ ability to distinguish medical misinformation and increase their willingness to pursue medical-related majors.


  • Open Access

    Endocrine therapy resistance of breast cancer: Important role of G protein-coupled estrogen receptor (GPER) and new therapeutic strategies

    by Tenghua Yu, Chongwu He, Hui Zhang, Yi Zhu, Annie Wang, Xiaoqiang Zeng, Yanxiao Huang, Jiamin Zhong, Xingye Wu, Yi Shu, et al.

    Breast cancer is the most prevalent malignancy that affects women worldwide, with approximately 70% of cases classified as hormone receptor-positive (HR+). Endocrine therapy is one of the principal treatment modalities for this patient cohort. However, a considerable proportion of tumors acquire resistance to endocrine therapeutics, resulting in reduced effectiveness as the disease progresses, but the underlying mechanisms are not fully characterized. The G protein-coupled estrogen receptor (GPER), a component of the G protein-coupled receptor family, is hypothesized to mediate estrogenic effects independently of conventional estrogen receptors. In recent years, our research group and others have demonstrated that GPER plays a crucial role in facilitating the clinical progression of HR+ breast cancer and significantly contributes to endocrine resistance. In this review, we summarize the diverse mechanisms through which GPER mediates endocrine resistance, encompassing somatic alterations, epigenetic and non-genetic variations, and modifications within the tumor microenvironment. Furthermore, we discuss GPER as a potential therapeutic target for overcoming endocrine resistance of HR+ breast cancer in future clinical applications.


  • Open Access

    Significance of SUMOylation in breast cancer progression: a comprehensive investigation using single-cell analysis and bioinformatics

    by Wenxing He, Zhengkui Sun, Dongmei Li, Tenghua Yu

    Background: Breast cancer remains a major global health challenge because of limitations in early detection and therapeutic outcomes. This study employed bulk and single-cell RNA sequencing to investigate SUMOylation-associated molecular networks, aiming to identify prognostic biomarkers and potential therapeutic applications. Methods: Transcriptomic profiling was performed on 1,445 breast cancer and 113 normal samples to identify differentially expressed genes. Four hub genes, NR3C2 , CDCA8 , AURKA , and PLK1 , were prioritized using machine learning. Consensus clustering stratified patients into molecular subtypes based on the hub gene expression patterns. Differential immune infiltration analysis was used to evaluate 28 immune cell populations between the subtypes. Hub gene-immune cell interactions were visualized using bubble diagrams. Pharmacogenomic sensitivity profiling was performed using subtype-specific drug response data. Single-cell sequencing identified epithelial subclusters enriched for hub genes, and transcription factor networks were analyzed using SCENIC. Pan-cancer validation was performed to assess the oncogenic role of hub genes in 21 malignancies. Statistical significance was determined using the Student’s t -test ( p < 0.0001). Results: Tumor tissues exhibited significant upregulation of CDCA8 , AURKA , and PLK1 , whereas NR3C2 was notably downregulated ( p < 0.0001). Consensus clustering identified two distinct molecular subtypes: Subtype1, characterized by NR3C2 upregulation and poorer prognosis, and Subtype2, distinguished by enhanced expression of CDCA8 , AURKA , and PLK1 , correlating with favorable outcomes. Notably, PIK3CA mutations were prevalent in Subtype1, whereas TP53 mutations dominated Subtype2. Immune infiltration profiles differed significantly between the two subtypes for most immune cell types. Pharmacogenomic assessments revealed distinct drug sensitivity profiles for each subtype in response to various therapeutic agents. A pan-cancer analysis of the four hub genes demonstrated consistent expression patterns, immune correlations, and prognostic associations across malignancies. Conclusion: Our findings reveal that SUMOylation subtypes in breast cancer exhibit distinct prognostic, immunological and pharmacogenomic profiles. These insights may provide candidate biomarkers for future personalized treatment strategies for breast cancer and potentially for other malignancies.


  • Open Access

    GPER in metabolic homeostasis and disease: molecular mechanisms, nutritional regulation, and therapeutic potential

    by Liyan Liu, Yutao Zhou, Jing Liu, Xinmiao Zhang, Chongwu He, Xiaoqiang Zeng, Rebeka Dejenie, Usman Zeb, Qiao Zeng, Lan Liu, et al.

    G protein-coupled estrogen receptor (GPER) significantly influences metabolic regulation by engaging multiple signaling pathways that affect overall metabolic health. Its structure and signaling mechanisms drive its diverse roles. Our team and others have successfully demonstrated that GPER modulates nutrient metabolism, spanning glucose, protein, and lipid metabolism, while also contributing to vitamin and mineral metabolism. Studies have linked GPER to metabolic disorders, including type 2 diabetes, nonalcoholic fatty liver disease, metabolic syndrome, and cardiovascular diseases, as well as thyroid disorders, highlighting its wide-reaching metabolic impact. GPER holds promise for energy balance and weight management by regulating energy expenditure and thermogenesis. Moreover, it appears to influence the metabolism of cancer cells during tumor progression. Rapid advancements in GPER agonist and antagonist research have highlighted the therapeutic potential of GPER agonists for treating metabolic diseases. Further investigations into GPER biology, mechanisms, and clinical applications will support novel therapeutic strategies, establishing GPER as a key target in metabolic research and treatment.


  • Open Access

    Microenvironmental G protein‐coupled estrogen receptor‐mediated glutamine metabolic coupling between cancer‐associated fibroblasts and triple‐negative breast cancer cells governs tumour progression

    by Chongwu He, Meixi Peng, Xiaoqiang Zeng, Hanzhi Dong, Zhengkui Sun, Jiawei Xu, Manran Liu, Liyan Liu, Yanxiao Huang, Zhiqiang Peng, et al.

    Background: Triple‐negative breast cancer (TNBC) is a particularly aggressive type of breast cancer, known for its lack of effective treatments and unfavorable prognosis. The G protein‐coupled estrogen receptor (GPER), a novel estrogen receptor, is linked to increased malignancy in various cancers. However, its involvement in the metabolic regulation of cancer‐associated fibroblasts (CAFs), a key component in the tumour microenvironment, remains largely unexplored. This study investigates how GPER influences the metabolic interaction between CAFs and TNBC cells, aiming to identify potential therapeutic targets.Methods: The co‐culture system is performed to examine the interaction between CAFs and TNBC cells, with a focus on GPER‐mediated glutamine production and release by CAFs and its subsequent uptake and utilization by TNBC cells. The definite roles of microenvironmental GPER/cAMP/PKA/CREB signalling in regulating the expression of glutamine synthetase (GLUL) and lactate dehydrogenase B (LDHB) are further investigated.Results: Our findings reveal that estrogen‐activated GPER in CAFs significantly upregulates the expression of GLUL and LDHB, leading to increased glutamine production. This glutamine is then secreted into the extracellular matrix and absorbed by TNBC cells, enhancing their viability, motility, and chemoresistance both in vitro and in vivo. TNBC cells further metabolize the glutamine through the glutamine transporter (ASCT2) and glutaminase (GLS1) axes, which, in turn, promote mitochondrial activity and tumour progression.Conclusions: The study identifies GPER as a critical mediator of metabolic coupling between CAFs and TNBC cells, primarily through glutamine metabolism. Targeting the estrogen/GPER/glutamine signalling axis in CAFs offers a promising therapeutic strategy to inhibit TNBC progression and improve patient outcomes. This novel insight into the tumour microenvironment highlights the potential of metabolic interventions in treating TNBC.Key points: Estrogen‐activated GPER in CAFs enhances GLUL and LDHB expression via the cAMP/PKA/CREB signalling, facilitating glutamine production and utilization. Microenvironmental GPER‐induced glutamine serves as a crucial mediator of metabolic coupling between CAFs and TNBC cells, boosting tumour progression by enhancing mitochondrial function. Targeting the glutamine metabolic coupling triggered by estrogen/GPER/GLUL signalling in CAFs is a promising therapeutic strategy for TNBC treatment.


  • Open Access

    Advances in immune regulation of the G protein-coupled estrogen receptor

    by Hanzhi Dong, Xiaoqiang Zeng, Jiawei Xu, Chongwu He, Zhengkui Sun, Liyan Liu, Yanxiao Huang, Zhe Sun, Yuan Cao, Zhiqiang Peng, et al.


  • Open Access

    Case report: Report of a rare encounter: metastasis of renal cell carcinoma to the thyroid

    by Siyi Xu, Jiawei Xu, Chengdong Yu, Ying Zeng, Lei Tang, Mu Tang, Tenghua Yu, Zhengkui Sun, Xiaofang Zhang

    Renal cell carcinoma (RCC) is the most common renal tumor, with lung, bone, and liver being the primary sites of metastasis. Thyroid metastasis, on the other hand, is relatively uncommon. Metastatic tumors in the thyroid gland typically manifest as multiple or isolated nodules, which can be easily overlooked due to the lack of specific clinical and imaging features. However, the identification of thyroid metastasis suggests the presence of systemic metastasis and is indicative of a poor prognosis for patients. In this paper, we present two cases of thyroid metastasis following nephrectomy, with the objective of enhancing understanding among medical community regarding the diagnosis and treatment of thyroid metastasis originating from renal cell carcinoma. By raising awareness about this phenomenon, we emphasize the importance of early detection and diagnosis to improve patient prognoses. The implementation of standardized treatment protocols at the earliest possible stage is also emphasized. Through this research, we aim to contribute to the early identification and management of thyroid metastasis in patients with renal cell carcinoma, ultimately leading to improved outcomes.


  • Open Access

    Visualization of breast cancer-related protein synthesis from the perspective of bibliometric analysis

    by Jiawei Xu, Chengdong Yu, Xiaoqiang Zeng, Weifeng Tang, Siyi Xu, Lei Tang, Yanxiao Huang, Zhengkui Sun, Tenghua Yu

    Breast cancer, as a daunting global health threat, has driven an exponential growth in related research activity in recent decades. An area of research of paramount importance is protein synthesis, and the analysis of specific proteins inextricably linked to breast cancer. In this article, we undertake a bibliometric analysis of the literature on breast cancer and protein synthesis, aiming to provide crucial insights into this esoteric realm of investigation. Our approach was to scour the Web of Science database, between 2003 and 2022, for articles containing the keywords “breast cancer” and “protein synthesis” in their title, abstract, or keywords. We deployed bibliometric analysis software, exploring a range of measures such as publication output, citation counts, co-citation analysis, and keyword analysis. Our search yielded 2998 articles that met our inclusion criteria. The number of publications in this area has steadily increased, with a significant rise observed after 2003. Most of the articles were published in oncology or biology-related journals, with the most publications in Journal of Biological Chemistry, Cancer Research, Proceedings of the National Academy of Sciences of the United States of America, and Oncogene. Keyword analysis revealed that “breast cancer,” “expression,” “cancer,” “protein,” and “translation” were the most commonly researched topics. In conclusion, our bibliometric analysis of breast cancer and related protein synthesis literature underscores the burgeoning interest in this research. The focus of the research is primarily on the relationship between protein expression in breast cancer and the development and treatment of tumors. These studies have been instrumental in the diagnosis and treatment of breast cancer. Sustained research in this area will yield essential insights into the biology of breast cancer and the genesis of cutting-edge therapies.


  • Open Access

    Visualization of the relationship between fungi and cancer from the perspective of bibliometric analysis

    by Jiawei Xu, Ying Zeng, Chengdong Yu, Siyi Xu, Lei Tang, Xiaoqiang Zeng, Yanxiao Huang, Zhengkui Sun, Bin Xu, Tenghua Yu


  • Open Access

    Breast mass as the first sign of metastasis from rectal carcinoma: a case report and review of the literature

    by Jiawei Xu, Chao Liu, Chengdong Yu, Tenghua Yu, Fan Fan, Xiaofang Zhang, Chuansheng Huang, Wen Chen, Zhengkui Sun, Meng Zhou

    We present a case report of a 41-year-old woman who developed a left breast mass 18 months after undergoing Dixon rectal cancer surgery. The purpose of this case report is to highlight the possibility of breast metastases in patients with colorectal cancer and emphasize the importance of careful evaluation and follow-up as well as timely and accurate diagnosis and management of the metastatic disease. During the physical examination in 2021, we noted that the lower border of the mass was 9 cm from the anal verge and that it occupied approximately one-third of the intestinal lumen. A pathological biopsy revealed the mass in the patient’s intestinal lumen was a rectal adenocarcinoma. The patient underwent Dixon surgery for rectal cancer and received subsequent chemotherapy. The patient had no prior history of breast-related medical conditions or a family history of breast cancer. During the current physical examination, we discovered multiple lymphadenopathies in the patient’s left neck, bilateral axillae, and left inguinal region, but none elsewhere. We observed a large erythema of about 15x10 cm on the patient’s left breast, with scattered hard nodes of varying sizes. Palpation of the area beyond the upper left breast revealed a mass measuring 3x3 cm. We conducted further examinations of the patient, which revealed the breast mass and lymphadenopathy on imaging. However, we did not find any other imaging that had significant diagnostic value. Based on the patient’s conventional pathology and immunohistochemical findings, combined with the patient’s past medical history, we strongly suspected that the patient’s breast mass was of rectal origin. This was confirmed by the abdominal CT performed afterward. The patient was treated with a chemotherapy regimen consisting of irinotecan 260 mg, fluorouracil 2.25 g, and cetuximab 700 mg IV drip, which resulted in a favorable clinical response. This case illustrates that colorectal cancer can metastasize to unusual sites and underscores the importance of thorough evaluation and follow-up, particularly when symptoms are atypical. It also highlights the importance of timely and accurate diagnosis and management of metastatic disease to improve the patient’s prognosis.